These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 30428474)

  • 21. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis.
    Huang E; Esrailian E; Spiegel BM
    Aliment Pharmacol Ther; 2007 Oct; 26(8):1147-61. PubMed ID: 17894657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rifaximin for the treatment of hepatic encephalopathy.
    Mantry PS; Munsaf S
    Transplant Proc; 2010 Dec; 42(10):4543-7. PubMed ID: 21168733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial.
    Patel VC; Lee S; McPhail MJW; Da Silva K; Guilly S; Zamalloa A; Witherden E; Støy S; Manakkat Vijay GK; Pons N; Galleron N; Huang X; Gencer S; Coen M; Tranah TH; Wendon JA; Bruce KD; Le Chatelier E; Ehrlich SD; Edwards LA; Shoaie S; Shawcross DL
    J Hepatol; 2022 Feb; 76(2):332-342. PubMed ID: 34571050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy.
    Hayakawa Y; Tamaki N; Nakanishi H; Kurosaki M; Tanaka Y; Inada K; Ishido S; Kirino S; Yamashita K; Nobusawa T; Matsumoto H; Kakegawa T; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Kaneko S; Yasui Y; Takahashi Y; Tsuchiya K; Okamoto R; Izumi N
    Intern Med; 2023 Apr; 62(7):973-978. PubMed ID: 36070941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort.
    Bajaj JS; O'Leary JG; Tandon P; Wong F; Kamath PS; Biggins SW; Garcia-Tsao G; Lai J; Fallon MB; Thuluvath PJ; Vargas HE; Maliakkal B; Subramanian RM; Thacker LR; Reddy KR
    Aliment Pharmacol Ther; 2019 Jun; 49(12):1518-1527. PubMed ID: 31032966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Durability of rifaximin response in hepatic encephalopathy.
    Neff GW; Jones M; Broda T; Jonas M; Ravi R; Novick D; Kaiser TE; Kemmer N
    J Clin Gastroenterol; 2012 Feb; 46(2):168-71. PubMed ID: 22011586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with Rifaximin in Cirrhosis: implications for the gut-liver-brain axis.
    Ahluwalia V; Wade JB; Heuman DM; Hammeke TA; Sanyal AJ; Sterling RK; Stravitz RT; Luketic V; Siddiqui MS; Puri P; Fuchs M; Lennon MJ; Kraft KA; Gilles H; White MB; Noble NA; Bajaj JS
    Metab Brain Dis; 2014 Dec; 29(4):1017-25. PubMed ID: 24590688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy.
    Flamm SL
    Am J Med Sci; 2018 Sep; 356(3):296-303. PubMed ID: 30286824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of rifaximin in management of hepatic encephalopathy.
    Wahib AA; El-Deen Salem MN; Ahmed MA; El-Dessouky YM; El-Tiby DM; El-Mola K; El-Sayed AM
    J Egypt Soc Parasitol; 2014 Dec; 44(3):677-85. PubMed ID: 25643509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy.
    Bajaj JS; Heuman DM; Sanyal AJ; Hylemon PB; Sterling RK; Stravitz RT; Fuchs M; Ridlon JM; Daita K; Monteith P; Noble NA; White MB; Fisher A; Sikaroodi M; Rangwala H; Gillevet PM
    PLoS One; 2013; 8(4):e60042. PubMed ID: 23565181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Small Intestinal Bacterial Overgrowth Diagnosed by a Breath Test and Improved by Rifaximin in a Patient with Hepatic Encephalopathy and Alcoholic Liver Cirrhosis.
    Sakamaki A; Yokoyama K; Yamazaki F; Kamimura H; Kamimura K; Takamura M; Yokoyama J; Terai S
    Intern Med; 2020 Aug; 59(15):1849-1853. PubMed ID: 32321898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy.
    Leevy CB; Phillips JA
    Dig Dis Sci; 2007 Mar; 52(3):737-41. PubMed ID: 17245628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Outcomes of Oral Zinc Therapy in Hepatic Encephalopathy Treatment.
    Fritz MK; Mangino AA; Hunt TV; Pitcock CT; Dugan AJ; Karri K; Yarra P
    Ann Pharmacother; 2023 Aug; 57(8):899-906. PubMed ID: 36367093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis.
    Bajaj JS; Pinkerton SD; Sanyal AJ; Heuman DM
    Hepatology; 2012 Apr; 55(4):1164-71. PubMed ID: 22135042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy.
    Wang Z; Chu P; Wang W
    Drug Des Devel Ther; 2019; 13():1-11. PubMed ID: 30587923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases.
    Bajaj JS; Barbara G; DuPont HL; Mearin F; Gasbarrini A; Tack J
    Dig Liver Dis; 2018 Aug; 50(8):741-749. PubMed ID: 29807873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current approach to treatment of minimal hepatic encephalopathy in patients with liver cirrhosis.
    Moran S; López-Sánchez M; Milke-García MDP; Rodríguez-Leal G
    World J Gastroenterol; 2021 Jun; 27(22):3050-3063. PubMed ID: 34168407
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis.
    Prakash RK; Kanna S; Mullen KD
    Clin Ther; 2013 Sep; 35(9):1458-73. PubMed ID: 23972578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications.
    Ponziani FR; Gerardi V; Pecere S; D'Aversa F; Lopetuso L; Zocco MA; Pompili M; Gasbarrini A
    World J Gastroenterol; 2015 Nov; 21(43):12322-33. PubMed ID: 26604640
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is Lactulose Plus Rifaximin Better than Lactulose Alone in the Management of Hepatic Encephalopathy?
    Butt NI; Butt UI; Kakar AATK; Malik T; Siddiqui AM
    J Coll Physicians Surg Pak; 2018 Feb; 28(2):115-117. PubMed ID: 29394969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.